|WHAT'S NEW ABOUT PARKINSON:
Latest scientific news selected for you
Gene interaction increases risk of Parkinsonís disease in women
Environmental factors may be more important in men (13-Apr-03)
Surgery for Parkinson's: is the evidence reliable?
Poor quality, too few patients, short follow-up, lack of control groups reduce the value of the clinical data now available. (11-Apr-03)
Potential genetic link between pesticide exposure and movement disorders
Neurological disease may result from pesticide interaction with NTE gene deficit (11-Apr-03)
Selegiline and cold remedies.
Patients taking selegiline should avoid pseudoephedrine and dextromethorphan containing cold medications. (01-Apr-03)
Colonic transit time (CTT) in PD.
Slow colonic transit, together with other contributing factors, leads to constipation in PD patients. (01-Apr-03)
Anti-inflammatory compounds ďbreakĒ the amyloid plaques of Alzheimerís disease
The mechanism could explain why patients on chronic antiinflammatory treatment have a lower risk of Alzheimerís disease (30-Mar-03)
Memory directing action is impaired in Parkinsonís disease
The defect is due to dopamine depletion in the caudate nucleus (30-Mar-03)
Alpha-synuclein linked to neuromelanin in Parkinsonís disease
More evidence in favour of current theory on the causes of the disease (25-Mar-03)
Aggregation of alpha-synuclein in Parkinson's.
The activity of an enzyme, tissue transglutaminase, leads to alpha-synuclein aggregation to form Lewy bodies and contributes to neurodegeneration. (23-Mar-03)
Why PD patients have difficulties rising from a chair?
Reduced strength in the hip may be a contributing factor. (15-Mar-03)
GDNF in a clinical trial in PD.
Glial cell line-derived neurotrophic factor (GDNF) does not improve parkinsonism in patients when intraventricularly given. (14-Mar-03)
Neuroimages illustrate how voice therapy works in patients with Parkinsoní s disease
After Lee Silverman Voice Treatment language activates more automatic circuits (14-Mar-03)
Treatment of sleep disorders in PD.
A nonspecific approach and a specific therapy of the various types of sleep and arousal disturbances are suggested in this review. (14-Mar-03)
Genotype does not predict the response of parkinsonian patients to COMT inhibitors
Pharmacogenomics does not measure up to expectations (11-Mar-03)
A patch for parkinsonian patients
A new patch formulation of selegiline is in development in the US (11-Mar-03)
Marijuana receptor agonist reduces levodopa-induced diskinesias
Nabilone effective in an animal model of Parkinsonís disease (11-Mar-03)
It is important to evaluate cognitive function in Parkinsonís disease
Memory impairment is related to the development of dementia in the long term (02-Mar-03)
A novel target for anti-parkinsonian therapy?
The role of torsin proteins, recognised in a tiny worm model, is connected with a number of neurological syndromes. (28-Feb-03)
Brain parenchyma sonography contributes to differential diagnosis of Parkinsonís disease
Hyperechogenicity areas detected in the substantia nigra almost exclusively in parkinsonian patients (25-Feb-03)
Eating less protects against neurodegeneration
Caloric restriction protects neurons from degeneration in animal models of Parkinsonís disease (24-Feb-03)
Treatment of sialorrhea
Clonidine is useful in the management of drooling, a common symptom of PD. (22-Feb-03)
Efficacy of Cinese electro-acupuncture in Parkinsonís disease explained
The technique reduces neuronal degeneratioin and increases brain neurotrophic factor (17-Feb-03)
Molecular fingerprints and multiple daily turnover in neurons are the biological basis of learning and memory
Important discoveries on the remodelling of neuronal connections for the understanding of neurodegeneration in Alzheimerís and Parkinsonís disease (12-Feb-03)
Late initiation of levodopa treatment in long-standing PD.
The decision of when to initiate levodopa therapy should be taken according to the patient's needs. (12-Feb-03)
Carotid body graft in parkinsonian rats.
Long- term functional recovery is due to trophic restoration of the dopaminergic pathways. (12-Feb-03)
Apathy is a symptom of Parkinsonís disease
The degree of apathy in Parkinsonian patients is not related to depression or anxiety (08-Feb-03)
Amyloid-beta deposition in parkinsonian brains.
This phenomenon could contribute to dementia when combined with other changes. (08-Feb-03)
Treatment of psychosis in Parkinson's.
Clozapine is the best choice currently available. (08-Feb-03)
Parkinsonism associated with mutations in the DJ-1 gene.
A collaborative group of european scientists proves that loss of DJ-1 function leads to neurodegeneration. (08-Feb-03)
Repeated exposure to neurotoxins at various ages is necessary before Parkinsonís disease appears
Only mice exposed to pesticides during their development and as adults develop the disease (08-Feb-03)
Viagra corrects a side effect of antidepressants
The drug improves sexual function in depressed patients on treatment (08-Feb-03)
Cholinesterase inhibitors improve psychiatric symptoms in Alzheimerís disease
Hallucinations, agitation and paranoia are reduced (08-Feb-03)
Proteasomal function in sporadic PD.
Failure of the ubiquitin-proteasome system may underline degeneration of substantia nigra also in the commonest form of PD. (23-Jan-03)